Psychiatric medication management for Jupiter — residential-level optimization, 45 minutes away.

RECO Immersive sits 32 miles south of Jupiter on I-95 — a 45-minute drive that puts residential-level psychiatric medication management within reach for families in Abacoa, Tequesta, and Jonathan's Landing. The psychiatry team is on the unit daily rather than by appointment, which means lithium and valproate titrations, atypical antipsychotic switches, and augmentation decisions get made against observed adherence and same-day side-effect data — not against outpatient self-report at the next two-week check-in.

The drive from Jupiter to RECO Immersive’s Delray Beach campus runs 32 miles south on I-95 — about 45 minutes outside of rush hour. For families in Abacoa, Jupiter Inlet Colony, or Tequesta, that distance is short enough to make structured family programming realistic and long enough that the campus offers genuine separation from local triggers. When an outpatient medication trial has stalled — partial response, breakthrough symptoms, or side effects that keep forcing dose reductions — a residential admission changes what psychiatry can actually do with the regimen.

What observed adherence and daily monitoring change

In outpatient care, whether a client actually takes a medication as prescribed is a matter of self-report and, occasionally, pill counts. In a residential setting, adherence is observed at every dose. That distinction is not academic. For medications with narrow therapeutic windows — lithium (target 0.6–1.2 mEq/L), valproate (50–125 mcg/mL), lamotrigine during titration — a missed or doubled dose is the difference between a clean trough and a level that either fails to explain nonresponse or drives unnecessary regimen changes.

Observed adherence also compresses the feedback loop on side effects. Sedation from quetiapine, akathisia from aripiprazole, GI upset in the first two weeks of sertraline — outpatient clients frequently discontinue on their own between visits and present at the next appointment describing “the medication didn’t work.” In residential, the nurse charting the side effect at 8 a.m. and the psychiatrist adjusting at morning rounds close that loop the same day. Trials that would have failed outpatient because the client stopped taking the medication instead get preserved with dose adjustment, timing changes, or a targeted switch.

Comprehensive lab monitoring during the residential stay

Admission labs at RECO Immersive follow a standard baseline panel — CBC, CMP, TSH, B12 and folate, vitamin D, lipid panel, HbA1c, urine drug screen, and urine pregnancy where clinically indicated. On top of the baseline, medication-specific monitoring is built into the residential cadence rather than negotiated around outpatient scheduling. Lithium levels are drawn weekly during titration and after any dose change, timed as true 12-hour troughs. Valproate levels follow the same pattern. Clozapine, when it appears on a treatment plan, brings its own ANC monitoring schedule.

For clients on second-generation antipsychotics — olanzapine, quetiapine, aripiprazole, risperidone — metabolic panels bookend the stay. Weight, fasting glucose, HbA1c, and lipid trends drive whether the current agent stays or whether the risk-benefit calculation warrants a switch to a lower-metabolic-risk option. EKG is drawn on admission where QTc-prolonging combinations or preexisting cardiovascular risk warrant it and rechecked before discharge when the regimen has changed materially. Standardized measurement runs alongside the labs — PHQ-9 weekly, GAD-7 weekly, YBOCS where OCD is on the differential, ASRS where adult ADHD is being evaluated, MDQ during a bipolar spectrum workup, and C-SSRS at admission and on any change in suicidal ideation.

Coordination with concurrent interventional treatment

A meaningful portion of the residential population at RECO Immersive is enrolled in concurrent interventional treatment at RECO Health — a course of rTMS delivered at 120% of motor threshold with roughly 3,000 pulses per session over a six-week protocol, or a series of racemic ketamine or esketamine treatments dosed against a defined protocol. When the same clinical team runs the oral regimen and the interventional plan, the two tracks stop working at cross purposes.

That coordination matters practically. Antidepressant washout decisions before a ketamine series, whether to hold a benzodiazepine dose the night before an infusion, and how to sequence an SSRI cross-taper against an ongoing TMS course get made once, by clinicians who see the client at rounds. The oral regimen also has to interlock with the psychotherapy protocol — CBT and DBT skills training, EMDR for trauma, ACT for values-based work, and motivational interviewing where a substance use disorder is co-occurring. A benzodiazepine dose that blunts EMDR reprocessing, or a buspirone titration that lags a GAD-focused CBT course, defeats the therapy work regardless of the pharmacologic logic.

The medication plan the client leaves with

Discharge from Immersive is not the end of the medication decisions — it’s the point at which the regimen has to translate cleanly into outpatient care. Every client leaves with a written medication plan that documents current agents and doses, the rationale behind the regimen, the next-step contingencies if a symptom returns or a side effect emerges, and the monitoring schedule the outpatient prescriber should hold to. Lithium clients leave knowing when their next level is due. Antipsychotic clients leave with the next metabolic panel scheduled.

When the receiving prescriber is the RECO Health outpatient team, that handoff is internal and the treatment record moves with the client. When the receiving prescriber is a community psychiatrist in Palm Beach County or a primary care physician in Jupiter, the discharge summary is written for them — clinical enough to justify the decisions, structured enough to be usable in a 20-minute follow-up visit. The psychiatric medication management gains that residential care makes possible only hold in the community when the plan the client leaves with is legible to the person who inherits it.

What admission looks like from a Jupiter referral

Admission from Jupiter typically starts with a phone intake and benefits verification the same day. Prior to arrival, the admissions team collects a current medication list, recent lab results where available, the most recent psychiatric records, and a substance use history. The first 24 hours on campus include a comprehensive psychiatric evaluation, standardized rating scales driven by the presenting picture, a medical history and physical, and the baseline labs.

For clients arriving on complex regimens — polypharmacy from serial outpatient trials, incomplete records, or unclear rationale for combinations — the first several days are spent stabilizing rather than making major changes. Where alcohol or opioid use is co-occurring, CIWA-Ar and COWS scores drive initial withdrawal management, and medication-assisted treatment decisions — naltrexone for alcohol use disorder, buprenorphine for opioid use disorder — are made in coordination with the psychiatric regimen rather than after it. Deprescribing decisions and augmentation strategies come after the psychiatry team has enough observed data to justify them.

Insurance and admissions logistics from Jupiter

RECO Immersive works with most major commercial carriers, including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans from other states. Benefits verification is completed before admission so the family isn’t sorting out coverage after the client is on campus. For clients traveling the 45 minutes down I-95 from Jupiter, admissions coordinates ground transportation when driving isn’t safe, and family programming is scheduled in structured blocks that make the round trip worth the drive rather than requiring weekly short visits.

Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.